Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

venetoclax 47Cyclophosphamide 43Specimen Handling 42Cytarabine 41fludarabine 32Biopsy 31Azacitidine 25Rituximab 20Methotrexate 17fludarabine phosphate 16blinatumomab 16Vincristine 15Daunorubicin 15Dexamethasone 14ibrutinib 13Whole-Body Irradiation 13Prednisone 13Magnetic Resonance Spectroscopy 13Injections 13obinutuzumab 11merphos 11Mercaptopurine 11Filgrastim 11Calcium Dobesilate 11asciminib 10X-Rays 10Stem Cell Transplantation 10Mycophenolic Acid 10Doxorubicin 10decitabine and cedazuridine drug combination 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
CA-4948 × Other hematologic neoplasm × 30 days × Clear all
NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡